@article{0d4b45b1482a42c6a10215127e594ff6,
title = "Maximising the public health benefit of antimalarials",
abstract = "[No abstract available]",
keywords = "amodiaquine plus artesunate, antimalarial agent, artemether plus benflumetol, artesunate, artesunate plus mefloquine, dihydroartemisinin plus piperaquine, mefloquine, piperaquine, primaquine, artemisin, artemisinin derivative, lactone, antimalarial activity, antimalarial drug resistance, clinical trial, disease transmission, drug efficacy, gametocyte, glucose 6 phosphate dehydrogenase deficiency, hemolysis, human, letter, malaria falciparum, mixed infection, parasite control, Plasmodium falciparum, Plasmodium vivax, Plasmodium vivax malaria, priority journal, single drug dose, drug combination, drug effects, malaria, Plasmodium, procedures, Antimalarials, Artemisinins, Drug Therapy, Combination, Humans, Lactones, Malaria",
author = "Ric Price and DOUGLAS, {Nicholas (Nick)}",
year = "2010",
month = oct,
day = "1",
doi = "10.1016/S1473-3099(10)70192-4",
language = "English",
volume = "10",
pages = "654--655",
journal = "Lancet Infectious Diseases",
issn = "1473-3099",
publisher = "The Lancet Publishing Group",
number = "10",
}
